K190815 is an FDA 510(k) clearance for the BrainScope TBI. Classified as Brain Injury Adjunctive Interpretive Electroencephalograph Assessment Aid (product code PIW), Class II - Special Controls.
Submitted by Brainscope Company, Inc. (Bethesda, US). The FDA issued a Cleared decision on September 11, 2019 after a review of 166 days - an extended review cycle.
This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.1450 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Neurology review framework, consistent with the majority of Class II 510(k) submissions.
View all Brainscope Company, Inc. devices
NCT02477943
Completed
Observational
Industry-sponsored
Objective Brain Function Assessment of mTBI/Concussion in College Athletes
Objective Brain Function Assessment of mTBI From Initial Injury to Rehabilitation and Treatment Optimization in College Athletes
| Condition studied |
Brain Injuries, Traumatic; Concussion, Mild; Concussion, Brain; Concussion, Intermediate; Concussion, Severe |
| Eligibility |
All sexes
· 18 Years+
|
| Principal investigator |
Leslie Prichep, Ph.D. |
| Sponsor |
BrainScope Company, Inc.
(industry)
|
Started 2015-08-08
→
Primary completion 2017-02-20
→
Completed 2017-07-31
Primary outcome
Algorithm for Likelihood of being concussed
Secondary outcome
Advanced Neuroimaging in concussion
Study completed - no results published.
This trial concluded in 2017 but has not posted
results to ClinicalTrials.gov. Completed studies without public results are common
in industry-sponsored device trials; the data may be referenced in the
510(k) Summary PDF or remain unpublished.
View full study on ClinicalTrials.gov